Dapagliflozin Patent Expiration
Dapagliflozin is used for treating heart failure and type 2 diabetes. It was first introduced by Astrazeneca Ab
Dapagliflozin Patents
Given below is the list of patents protecting Dapagliflozin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Farxiga | US10973836 | Methods of treating heart failure with reduced ejection fraction | Mar 09, 2040 | Astrazeneca Ab |
| Farxiga |
US10973836 (Pediatric) | Methods of treating heart failure with reduced ejection fraction | Sep 09, 2040 | Astrazeneca Ab |
| Farxiga | US11826376 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | Jul 18, 2039 | Astrazeneca Ab |
| Farxiga |
US11826376 (Pediatric) | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | Jan 18, 2040 | Astrazeneca Ab |
| Farxiga | US11903955 | Methods of treating heart failure with reduced ejection fraction | Mar 09, 2040 | Astrazeneca Ab |
| Farxiga |
US11903955 (Pediatric) | Methods of treating heart failure with reduced ejection fraction | Sep 09, 2040 | Astrazeneca Ab |
| Farxiga | US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Farxiga | US6515117 | C-aryl glucoside SGLT2 inhibitors and method | Oct 04, 2025 | Astrazeneca Ab |
| Farxiga |
US6515117 (Pediatric) | C-aryl glucoside SGLT2 inhibitors and method | Apr 04, 2026 | Astrazeneca Ab |
| Farxiga | US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Farxiga | US7456254 | Polymer-based sustained release device | Jun 30, 2025 | Astrazeneca Ab |
| Farxiga |
US7456254 (Pediatric) | Polymer-based sustained release device | Dec 30, 2025 | Astrazeneca Ab |
| Farxiga | US7851502 | Pharmaceutical formulations containing an SGLT2 inhibitor | Aug 19, 2028 | Astrazeneca Ab |
| Farxiga |
US7851502 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor | Feb 19, 2029 | Astrazeneca Ab |
| Farxiga | US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same | Dec 16, 2029 | Astrazeneca Ab |
| Farxiga |
US7919598 (Pediatric) | Crystal structures of SGLT2 inhibitors and processes for preparing same | Jun 16, 2030 | Astrazeneca Ab |
| Farxiga | US8221786 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Farxiga |
US8221786 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor | Sep 21, 2028 | Astrazeneca Ab |
| Farxiga | US8329648 | Methods for treating diabetes and reducing body weight | Aug 18, 2026 | Astrazeneca Ab |
| Farxiga |
US8329648 (Pediatric) | Methods for treating diabetes and reducing body weight | Feb 18, 2027 | Astrazeneca Ab |
| Farxiga | US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Farxiga |
US8361972 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor | Sep 21, 2028 | Astrazeneca Ab |
| Farxiga | US8431685 | Polymer-based sustained release device | Apr 13, 2025 | Astrazeneca Ab |
| Farxiga |
US8431685 (Pediatric) | Polymer-based sustained release device | Oct 13, 2025 | Astrazeneca Ab |
| Farxiga | US8461105 | Polymer-based sustained release device | Apr 13, 2025 | Astrazeneca Ab |
| Farxiga |
US8461105 (Pediatric) | Polymer-based sustained release device | Oct 13, 2025 | Astrazeneca Ab |
| Farxiga | US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same | Jun 20, 2027 | Astrazeneca Ab |
| Farxiga |
US8501698 (Pediatric) | Crystal structures of SGLT2 inhibitors and processes for preparing same | Dec 20, 2027 | Astrazeneca Ab |
| Farxiga | US8685934 | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof | May 26, 2030 | Astrazeneca Ab |
| Farxiga |
US8685934 (Pediatric) | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof | Nov 26, 2030 | Astrazeneca Ab |
| Farxiga | US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Farxiga |
US8716251 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor | Sep 21, 2028 | Astrazeneca Ab |
| Farxiga | US8721615 | Ampoule comprising an ampoule holder | Jan 18, 2030 | Astrazeneca Ab |
| Farxiga |
US8721615 (Pediatric) | Ampoule comprising an ampoule holder | Jul 18, 2030 | Astrazeneca Ab |
| Farxiga | US8906851 | Method for treating diabetes | Aug 18, 2026 | Astrazeneca Ab |
| Farxiga |
US8906851 (Pediatric) | Method for treating diabetes | Feb 18, 2027 | Astrazeneca Ab |
| Farxiga | US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Farxiga | US9238076 | Polymer-based sustained release device |
Apr 15, 2024
(Expired) | Astrazeneca Ab |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Dapagliflozin Generics
Several generic applications have been filed for Dapagliflozin.
Given below is the list of companies who have filed for Dapagliflozin generic.
1. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 2 different strengths of generic version for Dapagliflozin. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 5MG | tablet | Discontinued | ORAL | N/A | Feb 22, 2022 |
| 10MG | tablet | Discontinued | ORAL | N/A | Feb 22, 2022 |